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Abstract
The purpose of this study is to estimate the national prevalence of parent-reported attention deficit/
hyperactivity disorder (ADHD) diagnosis and treatment among U.S. children 2–17 years of age 
using the 2016 National Survey of Children’s Health (NSCH). The NSCH is a nationally 
representative, cross-sectional survey of parents regarding their children’s health that underwent a 
redesign before the 2016 data collection. It included indicators of lifetime receipt of an ADHD 
diagnosis by a health care provider, whether the child currently had ADHD, and receipt of 
medication and behavioral treatment for ADHD. Weighted prevalence estimates were calculated 
overall and by demographic and clinical subgroups (n = 45,736). In 2016, an estimated 6.1 million 
U.S. children 2–17 years of age (9.4%) had ever received an ADHD diagnosis. Of these, 5.4 
million currently had ADHD, which was 89.4% of children ever diagnosed with ADHD and 8.4% 
of all U.S. children 2–17 years of age. Of children with current ADHD, almost two thirds (62.0%) 
were taking medication and slightly less than half (46.7%) had received behavioral treatment for 
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ADHD in the past year; nearly one fourth (23.0%) had received neither treatment. Similar to 
estimates from previous surveys, there is a large population of U.S. children and adolescents who 
have been diagnosed with ADHD by a health care provider. Many, but not all, of these children 
received treatment that appears to be consistent with professional guidelines, though the survey 
questions are limited in detail about specific treatment types received. The redesigned NSCH can 
be used to annually monitor diagnosis and treatment patterns for this highly prevalent and high-
impact neurodevelopmental disorder.
INTRODUCTION
Attention deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental 
disorder diagnosed in childhood (Perou et al., 2013), and it is characterized by chronic 
symptoms of inattention, impulsivity, and/or hyperactivity that lead to functional impairment 
experienced in multiple settings (American Psychiatric Association, 2013). Children and 
adolescents with ADHD are more likely to experience a variety of negative outcomes 
compared to their peers without the disorder, including lower academic attainment, impaired 
social functioning, increased risk of hospital admissions and injuries, increased substance 
use and risk of substance use disorder, and reduced income and participation in labor 
markets as adults (Fleming et al., 2017; Fletcher, 2014; Groenman, Janssen, & Oosterlaan, 
2017; Molina et al., 2013; Ros & Graziano, 2017). In 2013, U.S. health care expenditures 
for ADHD totaled $23 billion (Dieleman et al., 2016), and the annual societal costs 
including health care, education, and reduced family productivity associated with childhood 
ADHD in the United States have been estimated to range from $38 billion to $72 billion 
(Doshi et al., 2012).
Criteria for the diagnosis of ADHD are laid out in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) and were revised for the fifth edition published in 2013 (American 
Psychiatric Association, 2013). These changes included shifting the age of onset 
requirement from the presence of symptoms and impairment by age 7 years to the presence 
of some symptoms by age 12 years, reducing the number of symptoms required for a 
diagnosis for individuals 17 years of age and older, and providing clinical examples of 
symptoms that are more age appropriate for older adolescents and adults (Matte et al., 2015; 
Sibley, Waxmonsky, Robb, & Pelham, 2013). Children with ADHD are most commonly 
diagnosed by pediatricians or other primary care physicians (53%); approximately 14% of 
children with ADHD received their diagnosis from a psychologist (Visser, Zablotsky, 
Holbrook, Danielson, & Bitsko, 2015b). Similarly, approximately one in eight children with 
ADHD received treatment services from a psychologist, whereas the majority of children 
with ADHD receive their treatment from a physician (Olfson, Gameroff, Marcus, & Jensen, 
2003).
Clinical guidelines for the diagnosis and treatment of ADHD have been published for 
pediatricians and child and adolescent psychiatrists (American Academy of Child and 
Adolescent Psychiatry, 2007; American Academy of Pediatrics [AAP], 2011). In 2011, the 
AAP published updated clinical practice guidelines for ADHD, and this update included 
age-specific treatment recommendations for preschool-age children (4–5 years of age), 
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elementary-school-age children (6–11 years), and adolescents (12–18 years; AAP, 2011). 
For preschool-age children diagnosed with ADHD, the AAP recommends parent-or teacher-
administered behavior therapy as the first-line treatment, with medication prescribed only if 
impairment remains after an adequate trial of behavior therapy. For children 6–11 years of 
age, the AAP recommends prescribing medication and/or behavior therapy, with a 
preference for both treatments in combination, and for adolescents 12–18 years of age, 
medication is recommended with a preference for it to be prescribed in combination with 
behavior therapy. Combination therapy is also supported in practice parameters for child and 
adolescent psychiatrists, particularly for children who still have functional impairment while 
being treated with medication alone or for children who have ADHD and a co-occurring 
disorder (American Academy of Child and Adolescent Psychiatry, 2007). Clinical guidance 
published for child and adolescent psychiatrists also recommends the use of psychotherapy 
to treat very young children with ADHD before initiating medication treatment (Gleason et 
al., 2007). Receipt of recommended treatment for children and adolescents with ADHD has 
been identified as a developmental objective for the improvement of the nation’s health in 
Healthy People 2020, with the goal of increasing the proportion of children 4–5 years of age 
with ADHD who receive recommended behavioral treatment and increasing the proportion 
of children and adolescents 6–17 years of age who receive recommended behavioral 
treatment, medication treatment, or a combination of the two (United States Department of 
Health & Human Services, 2010).
National surveys are commonly used to monitor trends in the prevalence of ADHD 
diagnosis and treatment, and this information can be used to characterize service needs of 
children with ADHD and for identification of service gaps. A previous study using 
nationally representative data has shown that in 2011–2012 approximately 11% of children 
and adolescents 4–17 years of age had ever received an ADHD diagnosis from a health care 
provider (Visser et al., 2014). Data from two periodically administered national surveys have 
tracked an increase in diagnosed ADHD since the late 1990s and early 2000s (Akinbami, 
Liu, Pastor, & Reuben, 2011; Visser et al., 2014), with another study documenting an 
increase specifically in the population of children 2–5 years of age from 2007–2008 to 
2011–2012 (Danielson et al., 2017b). There was also a noted increase in the percentage of 
U.S. children taking ADHD medication during the same period; an estimated 4.8% of 
children 4–17 years of age had current ADHD and were taking ADHD medication in 2007–
2008 compared to 6.1% in 2011–2012 (Visser et al., 2014). Approximately 30%–40% of 
children and adolescents with current ADHD were reported to have been receiving 
behavioral or psychosocial treatments for their ADHD based on parent-reported national 
survey data (Danielson, Visser, Chronis-Tuscano, & DuPaul, 2017a; Visser et al., 2015a).
The purpose of the present study is to provide updated national prevalence estimates of 
ADHD diagnosis and treatment for children 2–17 years of age living in the United States 
based on National Survey of Children’s Health (NSCH) data collected in 2016. This 
iteration of the NSCH is the first after a major survey redesign and will provide baseline 
estimates for diagnosed ADHD prevalence and treatment indicators that can be used for 
trend analyses with future annual administrations of the NSCH.
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METHODS
The NSCH is a population-based, cross-sectional survey designed to monitor the health and 
well-being of noninstitutionalized children 0–17 years of age living in the United States. The 
survey is sponsored by the Health Resources and Services Administration’s Maternal and 
Child Health Bureau, and the U.S. Census Bureau started conducting this survey annually in 
2016. Previous versions of this survey had been conducted every 4 years as a telephone 
survey, but due to decreasing response rates and increasing costs for survey implementation, 
the NSCH was transitioned to an online/mail-based survey beginning with the 2016 data 
collection period (United States Census Bureau, 2017). Households were randomly selected 
for participation and mailed an invitation to complete a household screener and, if children 
were present, a child-specific questionnaire regarding the health and well-being of one 
randomly selected child living in the household. These survey components could be 
completed either online using a secure, confidential website or with a mailed paper version 
of the questionnaire. A full description of the survey methods has been published elsewhere 
(United States Census Bureau, 2017). There were 50,212 completed interviews for the 2016 
NSCH, with an overall weighted response rate of 40.7%; the proportion of screened 
households known to contain a child that completed the child-specific questionnaire was 
69.7%. This study included data on children 2–17 years of age and a valid response to the 
lifetime ADHD diagnosis question described next (n = 45,736).
This study focused on survey questions related to ADHD. The household respondent 
(generally a parent, and hereafter referred to as the parent) was asked if “a doctor or other 
health care provider ever told you that this child has attention deficit disorder or attention-
deficit/hyper-activity disorder, that is, ADD or ADHD.” If the parent responded 
affirmatively, he or she was directed to answer two follow-up questions: if the child 
currently has ADHD, and, if so, whether the child’s ADHD was mild, moderate, or severe. 
Parents were also asked if their child was “currently taking medication for ADD or ADHD,” 
if their child received “behavioral treatment for ADD or ADHD such as training or an 
intervention that you or this child received to help with his or her behavior” in the past 12 
months, and if their child “received any treatment or counseling from a mental health 
professional … [including] psychiatrists, psychologists, psychiatric nurses, or clinical social 
workers” in the past 12 months.
Weighted prevalence estimates and 95% Wald confidence intervals were calculated overall 
for ADHD diagnosis (ever received an ADHD diagnosis and reported to have current 
ADHD) and for each treatment type (receipt of ADHD medication, receipt of behavioral 
treatment for ADHD, receipt of behavioral treatment for ADHD and/or any treatment or 
counseling from a mental health professional) among children 2–17 years of age with 
current ADHD. Combinations of treatment specific to ADHD were considered by four 
mutually exclusive treatment groups: (a) medication and behavioral treatment for ADHD, 
(b) medication only, (c) behavioral treatment only, and (d) neither medication nor behavioral 
treatment. Receipt of any treatment or counseling from a mental health professional was not 
considered in the analysis of the mutually exclusive treatment groups. Weighted prevalence 
estimates were also calculated and compared using prevalence ratios (PRs) and 95% 
confidence intervals (CIs) by the following demographic subgroups: child sex (male, 
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female), age (2–5 years, 6–11 years, 12–17 years), race (White, Black, other), ethnicity 
(Hispanic, non-Hispanic), primary language in the home (English, Spanish, other language), 
highest education level in the household (less than high school, high school graduate, more 
than high school), poverty status (< 100% of federal poverty level, 100%–199% of federal 
poverty level, ≥ 200% of federal poverty level), type of health care coverage (public only, 
private only, private and public, insurance type unspecified, none), region of residence 
(Northeast, Midwest, South, West), and urban/rural status (lived in a Metropolitan Statistical 
Area [hereafter referred to as urban/suburban], did not live in a Metropolitan Statistical Area 
[hereafter referred to as rural]). For treatment type, comparisons were also made by parent-
reported ADHD severity (mild, moderate, severe) and presence of a current co-occurring 
mental, emotional, or behavioral condition (yes, no; hereafter referred to as a co-occurring 
condition). Current co-occurring conditions were identified with questions similar to those 
for ADHD (parent reported whether a health care provider had ever told them their child had 
the condition and whether the child currently has the condition). The conditions considered 
in this analysis included behavioral or conduct problems, anxiety problems, depression, 
autism spectrum disorder, Tourette syndrome, and substance use disorder.1
Among all children included in the analytic sample, there was a small percentage of missing 
data for each of the ADHD-related variables of interest. Of children with a reported lifetime 
ADHD diagnosis, 2.0% were missing for the current ADHD question; these children were 
considered in the analysis not to have current ADHD. Of children with current ADHD, 0.5% 
were missing for the medication variable, 0.4% were missing for behavioral treatment, and 
0.4% were missing for any treatment or counseling from a mental health professional. 
Respondents with missing data for one of these variables were excluded from the respective 
analyses on that treatment indicator. Missing data for five socio-demographic variables were 
imputed (United States Census Bureau, 2017). Child’s age (missing for 0.1% of the analytic 
sample), race (0.3%), and ethnicity (0.6%) were imputed using hot-deck imputation and the 
single imputed values were included in all relevant subgroup analyses. Household poverty 
ratio (missing for 18.7% of the analytic sample) and household educational attainment 
(3.0%) were multiply imputed using regression methods and analyses using these variables 
were conducted separately then merged using standard procedures for combining multiple 
imputation analyses (Little & Rubin, 2002). Children with missing data for any of the other 
demographic or clinical indicators were excluded from those subgroup comparisons. All 
analyses were conducted in SAS-callable SUDAAN version 11.0.1 (RTI International; Cary, 
NC) in order to account for the complex survey design and to apply sample weights that 
adjust for probability of selection, nonresponse, and the underlying demographic distribution 
of the target population.
RESULTS
In 2016, a weighted estimate of 6.1 million U.S. children 2–17 years of age (9.4%) had ever 
received an ADHD diagnosis by a doctor or other health care provider based on parent 
1The questions for the diagnosis of behavioral or conduct problems and substance use disorder also included educators (e.g., teachers 
and school nurses) along with doctors or other health care providers as providers who could have told parents that their child had these 
conditions.
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report. Of these, 5.4 million currently had ADHD, which was 89.4% of children who had 
ever been diagnosed with ADHD and 8.4% of all U.S. children 2–17 years of age.
The prevalence of having ever received an ADHD diagnosis and currently having ADHD by 
parent report was significantly different by each set of demographic groups compared (Table 
1). Boys, adolescents 12–17 years of age, Black children, non-Hispanic children, children 
living in households with English as the primary language, children in the lowest income 
bracket (i.e., living in households with income less than 100% of the federal poverty level), 
children with public insurance only or both public and private insurance, children living in 
the Midwest or South, and children living in rural areas were more likely to have ever 
received an ADHD diagnosis and to currently have ADHD than their respective 
counterparts. The weighted percentage of children ever diagnosed with ADHD increased 
with age, with 2.4% of young children (2–5 years; approximately 388,000 children), 9.6% of 
school-age children (6–11 years; 2.4 million), and 13.6% of adolescents (12–17 years; 3.3 
million) having ever received an ADHD diagnosis. The prevalence of current ADHD also 
increased with age, as 2.1% of young children (an estimated 335,000 children), 8.9% of 
school-age children (2.2 million), and 11.9% of adolescents (2.9 million) were reported to 
currently have ADHD. For boys, the prevalence of ever-diagnosed and current ADHD was 
highest at age 12, whereas the prevalence for girls for ever having received an ADHD 
diagnosis was highest at age 16 (Figure 1).
Among children with current ADHD, 14.5% were reported to have severe ADHD, 43.7% 
had moderate ADHD, and 41.8% had mild ADHD. Nearly two thirds (63.8%) of children 
with current ADHD had at least one current co-occurring condition; behavioral or conduct 
problems were the most common type of co-occurring condition reported (51.5% of all 
children with current ADHD), followed by anxiety problems (32.7%), depression (16.8%), 
autism spectrum disorder (13.7%), and Tourette syndrome (1.2%). A small percentage 
(1.0%) of adolescents 12–17 years of age with current ADHD had a parent-reported current 
substance use disorder.
Of children with current ADHD, 62.0% were reported to be currently taking medication for 
their ADHD, representing 5.1% of all U.S. children 2–17 years of age (approximately 3.3 
million children). There was not a statistically significant difference in the weighted 
estimates of ADHD medication use between boys and girls with current ADHD; however, 
non-Hispanic children, children living in homes where English was the primary language, 
and children living in the South were more likely to be taking medication than their 
counterparts (Table 2). There was also a statistically significant difference in medication 
rates by age group. Young children 2–5 years of age with current ADHD were less likely to 
be taking ADHD medication (18.2%; approximately 61,000 young children) than school-age 
children (68.6%, PR = 3.76, 1.5 million), 95% CI [2.05, 6.91], or adolescents (62.1%, PR = 
3.41, 1.8 million), 95% CI [1.86–6.27]. The age at which the highest percentage of children 
with current ADHD were taking medication was 11 years (Figure 2). Children with mild 
ADHD (46.1%) were less likely to be taking medication than children with moderate ADHD 
(70.3%, PR = 1.53), 95% CI [1.36, 1.72], or severe ADHD (81.6%, PR = 1.77), 95% CI 
[1.56, 2.01] (Table 2). Children with current ADHD and a current co-occurring condition 
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were more likely to be taking ADHD medication (66.6%, PR = 1.23), 95% CI [1.10, 1.38], 
than children without a reported co-occurring condition (54.0%).
Slightly less than half of children with current ADHD had received a behavioral treatment 
for their ADHD in the past 12 months (46.7%; 2.5 million children). The overall patterns of 
demographic differences for behavioral treatment rates were different than for ADHD 
medication (Table 2). Adolescents were less likely to have received behavioral treatment 
than younger children, and boys were more likely than girls to have received behavioral 
treatment. Black children were more likely than White children, and children with public 
insurance alone were more likely than children with private insurance alone, to have 
received behavioral treatment. Children living in the South or Midwest and children living in 
a rural area were less likely to receive behavioral treatment than children living in the West 
or in an urban/suburban area, respectively. However, similar to medication rates, behavioral 
treatment rates were higher for those with more severe ADHD and for children with a 
current co-occurring condition. Children 2–3 years of age with current ADHD had the 
highest percentage of behavioral treatment receipt in the past year (77.4%), followed by 
children 6 years of age (59.3%) and children 4–5 years of age (55.4%; Figure 2).
Among children who were reported not to have received behavioral treatment for their 
ADHD in the past 12 months (53.3% of children with current ADHD), nearly one fourth 
(24.4%) were reported to have received treatment or counseling from a mental health 
provider in the previous 12 months. Overall, 59.9% of children and adolescents with current 
ADHD had received behavioral treatment for their ADHD and/or any treatment or 
counseling from a mental health professional in the prior year. There were slight differences 
in the treatment patterns by demographic subgroups when receipt of any mental health 
treatment or counseling from a mental health professional is considered along with 
behavioral treatment specific to ADHD (Table 2). Of note, differences by sex, age, and race 
observed for receipt of behavioral treatment were narrowed or eliminated when the broader 
indicator of receipt of any mental health treatment (behavioral treatment for ADHD and/or 
treatment or counseling from a mental health professional) was examined in the analysis.
Considering combinations of current medication and behavioral treatment for ADHD in the 
past year, nearly one third of children with current ADHD had received both types of 
treatment (31.7%). More children had received medication alone (30.3%) than behavioral 
treatment alone (14.9%), and nearly one fourth (23.0%) had received neither treatment. 
There were significant differences in the combinations of medication and behavioral 
treatment by several demographic and clinical characteristics (Table 3). Young children 2–5 
years of age with current ADHD were most likely to receive behavioral treatment alone 
(45.8%) or neither treatment (36.0%), whereas older children were more likely to receive 
medication with or without behavioral treatment. Black children were most likely to get both 
medication and behavioral treatment, whereas White children were the most likely to receive 
medication alone. Nearly half of children with current ADHD and no health insurance 
received neither treatment (49.1%), compared to 19.3% to 31.0% of children with the other 
types of health insurance. Children living in the West were more likely to get behavioral 
treatment alone and less likely to get medication alone than children living in other parts of 
the country. Children living in rural areas were more likely to get neither treatment than 
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children living in urban/suburban areas. Children with severe ADHD and children with a 
current co-occurring condition were more likely to get medication and behavioral treatment 
together than children with mild or moderate ADHD and children with no co-occurring 
conditions, respectively; children with mild or moderate ADHD and children with no co-
occurring conditions were more likely to receive neither treatment than children with severe 
ADHD or any co-occurring condition.
DISCUSSION
This study provides an updated epidemiological profile of ADHD diagnosis and treatment 
among noninstitutionalized children 2–17 years of age in the United States using national 
survey data collected in 2016. These results indicate that there were approximately 6.1 
million children and adolescents in the United States who have ever received an ADHD 
diagnosis from a health care provider and 5.4 million children and adolescents who currently 
had ADHD. Approximately two thirds of children with current ADHD (62.0%) were 
currently taking medication for their ADHD, and slightly less than half (46.7%) had 
received behavioral treatment for ADHD during the previous 12 months.
Due to significant methodological changes in the sampling and administration of the NSCH 
(United States Census Bureau, 2017), the 2016 data on ADHD prevalence and medication 
use and data from the same survey in previous years are not directly comparable statistically. 
However, the estimated prevalence of ever-diagnosed ADHD from the 2016 NSCH was 
consistent with published estimates from the National Health Interview Survey and previous 
administrations of the NSCH (Figure 3; Bloom, Black, & Freeman, 2015; Bloom, Cohen, & 
Freeman, 2012; Bloom & Freeman, 2015; Bloom, Jones, & Freeman, 2013; Bloom & 
Simpson, 2016; Visser et al., 2014). Results from administrative claims data over a similar 
period (2009–2015) have suggested that there may be subgroup differences in trends of 
diagnosed prevalence over time by type of insurance; there has been a steady increase in the 
prevalence of diagnosed ADHD among children 6–17 years of age with employer-sponsored 
insurance, whereas the proportion of children in Medicaid diagnosed with ADHD has 
plateaued from 2012 to 2015 (Nyarko et al., 2017). Detection of these types of subgroup 
differences over time may be used to identify differences in frequency of diagnosis for 
subpopulations of children and to recognize changes in the underlying population of 
children being diagnosed with ADHD. The 2016 NSCH estimates provide an important 
baseline from which to evaluate forthcoming annual NSCH data to identify the patterns in 
trends over time for these ADHD prevalence and treatment indicators overall and by 
demographic subgroups.
Looking specifically at young children with ADHD, from 2007–2008 to 2011–2012, there 
was a 57% increase (from 1.0% to 1.5%) noted in the percentage of children 2–5 years of 
age with current ADHD (Danielson et al., 2017b). In the present study, an estimated 2.1% of 
children 2–5 years of age were reported to have current ADHD. This result provides 
additional evidence of an increasing trend in the prevalence of current ADHD in this age 
group, though there were differences in survey methodology for these sets of estimates. The 
higher prevalence observed for 2016 is consistent with a study of insurance claims data that 
showed an increase in the percentage of children 2–5 years of age receiving clinical care for 
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ADHD from 2008 to 2014 (Visser et al., 2016) and a study of electronic health record data 
that showed an increase in the percentage of children 4–5 years of age with pediatric clinic 
visits associated with ADHD care from 2008 to 2014, though the rate of increase had slowed 
in this population after implementation of the AAP guidelines in 2011 (Fiks et al., 2016).
This report presents prevalence estimates for both ever-diagnosed ADHD and current 
ADHD. These prevalence estimates and their relationship to associated demographic and 
clinical characteristics are similar because nearly 90% of children who had ever received an 
ADHD diagnosis were reported to currently have the disorder. There is an increasing 
acknowledgment of ADHD as a chronic condition with symptoms and impairment that can 
persist into adolescence and adulthood for many individuals who were diagnosed during 
childhood (Agnew-Blais et al., 2016; Faraone, Biederman, & Mick, 2006; Holbrook et al., 
2016). Changes made to the diagnostic criteria for ADHD in DSM-5 have broadened the 
definition of symptoms and impairment to be more applicable to older adolescents and 
adults, including changes to the minimum age of onset and symptom count, and use of 
symptom examples that relate to the expected behaviors of older adolescents and adults with 
ADHD. This combination of criteria changes may affect the number of adolescents and 
young adults who continue to meet diagnostic criteria for ADHD (Matte et al., 2015; 
McKeown et al., 2015) and shift the level of recognition on how ADHD-related symptoms 
and impairment persist beyond childhood.
The demographic patterns for report of a lifetime diagnosis of ADHD in children in 2016 
were generally similar to estimates from 2011–2012 (Visser et al., 2014), where boys, non-
Hispanic children, and children living in households with English as the primary language, 
in low-income households, with public insurance, or in the Midwest or South were more 
likely to have been diagnosed with ADHD than their counterparts. However, the pattern of 
diagnosed ADHD prevalence by race differed in 2016, where the proportion of Black 
children who have received an ADHD diagnosis was higher than for White children. 
Although it is possible that this difference is a function of the changes in NSCH survey 
methodology, this finding suggests that revisiting previously documented concerns about the 
underdiagnosis of ADHD in Black children (Coker et al., 2016; Morgan, Staff, Hillemeier, 
Farkas, & Maczuga, 2013) may be appropriate. Another demographic group with a higher 
prevalence of diagnosed ADHD is children living in rural areas, who were 30% more likely 
to have ever received an ADHD diagnosis than children living in urban or suburban areas. 
This disparity may be explained by the underlying distribution of demographic 
characteristics of children living in rural areas (Anderson, Neuwirth, Lenardson, & Hartley, 
2013). With the limited availability of behavioral health services in rural settings, Kelleher 
and Gardner (2017) suggested that strategies to ensure that children with ADHD living in 
rural areas receive appropriate care may be helpful in addressing this disparity.
This study also provides the first nationally representative estimates of the receipt of past-
year nonpharmacologi-cal behavioral treatment for ADHD among all U.S. children with 
ADHD. A recently published study (Danielson et al., 2017a) analyzed data from a 2014 
follow-back survey about children and adolescents with ADHD and showed that 62% of 
children with ADHD had received a psychosocial treatment during their lifetime, though this 
sample included only children who had the ADHD diagnosis for at least 2 years. Another 
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study using 2009–2010 survey data on the subset of children with current ADHD who also 
had special health care needs showed that less than half of these children received behavioral 
treatment in the past year (Visser et al., 2015a), which is consistent with the results from the 
2016 NSCH. Patterns of receipt of behavioral treatment for demographic and clinical 
subgroups were similar for these two populations by age, insurance status, ADHD severity, 
and presence of a co-occurring condition but differed from the previous study for region of 
residence such that, in 2016, children with ADHD living in the West had significantly higher 
rates of behavioral treatment than children living in in the South or Midwest, whereas the 
Northeast had the highest rates of behavioral treatment based on the 2009–2010 survey. 
These differences may reflect a change in receipt of behavioral treatment among these 
regional subgroups over time, though the differences in survey population, survey mode, and 
exact wording of the associated survey question may also have differentially affected how 
parents in different regions reported these types of treatments. In addition, patterns of 
estimates of the receipt of nonpharmacological treatments changed for some demographic 
subgroups when the receipt of any treatment or counseling from a mental health provider 
was considered. Although these children may have been receiving treatment for a co-
occurring condition or other problems rather than treatment for their ADHD specifically, 
care from a mental health provider may have indirectly had an impact on the expression of 
ADHD symptoms and experience of functional impairment. A clinical care algorithm for 
pediatricians on diagnosing and treating ADHD recognizes the importance of identifying 
and treating co-occurring conditions among children diagnosed with ADHD, which may 
include coordinating care with specialists and prioritizing management of the co-occurring 
condition before addressing treatment for ADHD (Wolraich, Brown, & Brown, 2011).
Reported combinations of received ADHD treatment are of particular interest, as clinical 
guidelines recommend different treatment combinations based on the age of the child with 
ADHD. Specifically, behavior therapy is recommended as the first-line treatment for young 
children with ADHD (AAP, 2011; Gleason et al., 2007), and medication is recommended or 
preferred in combination with behavior therapy for older children with ADHD (AAP, 2011). 
The age-specific differences in treatment guidelines for ADHD reflect the differing levels of 
evidence of effectiveness for behavioral treatment in alleviating symptoms and impairment 
related to ADHD. A comparative effectiveness review has shown that behavior therapy has a 
higher strength of evidence for effectiveness than medication in children with ADHD 
younger than 6 years while also avoiding the potential risks of adverse events associated 
with ADHD medications (Charach et al., 2013). Psychosocial treatments such as peer 
intervention and organization training have been found to be effective in school-age 
children, but there remains a gap in the development of nonpharmacological treatments that 
have been evaluated and shown to be effective for adolescents (Evans, Owens, & Bunford, 
2014).
The results from the 2016 NSCH suggest that the most common combinations of ADHD 
treatment by age group appear to be consistent with recommendations from clinical 
guidelines. For adolescents 12–17 years of age, the most common treatment type was 
medication alone (32.5%), followed by combined medication and behavioral treatment 
(29.7%), reflecting the recommendation for medication as the first-line treatment for ADHD 
in this age group, with a preference for the medication to be received in combination with 
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behavior therapy. For children with ADHD 6–11 years of age, the recommended treatment is 
medication in combination with behavior therapy, and two thirds of children with ADHD in 
this age group were receiving medication, with slightly more receiving medication in 
combination with behavioral treatment (37.3%) than medication alone (31.5%). Among 
young children 2–5 years of age with ADHD, nearly half (45.8%) were receiving behavioral 
treatment alone, followed by approximately one third (36.0%) receiving neither treatment. 
Nearly one out of five (18.2%) young children with ADHD were receiving medication with 
or without behavioral treatment. These findings represent considerably higher estimates of 
behavioral treatment alone and lower estimates of medication use among this young age 
group compared to a previous study, where 33.7% received behavioral treatment alone and 
44.0% had received medication, either with or without behavioral treatment (Danielson et 
al., 2017b). With regard to Healthy People 2020 objectives (United States Department of 
Health and Human Services, 2010), more than half (55.4%) of children 4–5 years of age 
with ADHD had received behavioral treatment for ADHD in the past year, and most children 
6–17 years of age had received medication, behavioral treatment, or both (82.8% of children 
6–11 years and 74.2% of adolescents 12–17 years). These results can serve as a baseline for 
the Healthy People 2020 objective to increase the proportion of children with ADHD who 
receive recommended treatments. However, it is important to note that these data provide 
only general indicators of types of treatment received and do not reflect the exact type, 
quality, duration, sequencing, or appropriateness of the medication or behavioral treatment 
received. Other national survey data from 2014 have shown that less than one third of 
children with ADHD have received evidence-based psychosocial treatments such as peer 
interventions or a parent who has received parent training (Danielson et al., 2017a), 
suggesting that there is likely a gap in the overall receipt of evidence-based 
nonpharmacological treatment.
This analysis is subject to several limitations. First, the data collected in this survey rely on 
parent report of diagnosis and treatment, and these indicators have not been validated against 
medical records or clinical judgment and may be subject to recall bias. However, previous 
work has shown that parent report of an ADHD diagnosis results in similar prevalence 
estimates to those attained through analysis of administrative claims data, suggesting 
convergent validity of estimated prevalence from both of these data sources (Visser, 
Danielson, Bitsko, Perou, & Blumberg, 2013). A second limitation is the lack of specificity 
for the question on receipt of behavioral treatment, as no examples were provided in the 
question and parents may have been unsure about which treatments should be reported in 
response to this question. This lack of specificity could potentially lead to an overestimate or 
underestimate of behavioral treatment receipt, depending on how parents interpret the 
question relative to the types of treatment and accommodations that their child has received 
for their ADHD. Relatedly, we were unable to distinguish the quality, type, or duration of 
the reported behavioral treatment, or specific types of medication, and therefore we cannot 
estimate the proportion of children with ADHD who were receiving recommended, 
evidence-based treatments. Finally, the overall response rate of 40.7% should be noted. This 
may have led to a biased sample; however, the development and application of sample 
weights to the analyses presented in this study were intended to attenuate bias resulting from 
nonresponse.
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This study provides updated national estimates of the prevalence of diagnosed ADHD 
among children and adolescents living in the United States and presents population-based 
estimates of the types of treatment these children were receiving for their ADHD. Although 
the estimated prevalence of ADHD diagnosis does not appear to have increased in the time 
since previous nationally representative estimates were published, a sizeable proportion of 
U.S. children and adolescents have been diagnosed with the disorder, which justifies the 
continued monitoring of the treatment received and outcomes of this population. This study 
has also examined how the types of treatment this population received relate to clinical 
guidelines and Healthy People 2020 goals. These estimates indicate that many, but not all, 
children with ADHD are receiving treatment that appears to be generally consistent with 
clinical recommendations from the AAP, though there is limited detail available regarding 
the specific types of treatments reported in response to these survey questions. Future 
iterations of the NSCH can be used to continue to monitor the diagnosis and treatment 
patterns for this highly prevalent and high-impact neurodevelopmental disorder during 
childhood and adolescence. This information can help clinicians understand ongoing trends 
in the frequency of the diagnosis of ADHD in the community and the types of treatment 
received by children with ADHD. Recognition of these trends is particularly important for 
clinical and school psychologists, as they can play an integral role in the diagnosis and 
treatment of children with ADHD, particularly for the administration of evidence-based 
behavioral treatments that have been shown to be effective in improving symptoms and 
outcomes for children with ADHD.
References
Agnew-Blais JC, Polanczyk GV, Danese A, Wertz J, Moffitt TE, Arseneault L. Evaluation of the 
persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young 
adulthood. JAMA Psychiatry. 2016; 73(7):713–720. [PubMed: 27192174] 
Akinbami LJ, Liu X, Pastor PN, Reuben CA. Attention deficit hyperactivity disorder among children 
aged 5–17 years in the united states, 1998–2009. Nchs Data Brief. 2011; 70:1–8.
American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and 
treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the 
American Academy of Child and Adolescent Psychiatry. 2007; 46(7):894–921. [PubMed: 
17581453] 
American Academy of Pediatrics. ADHD: Clinical practice guideline for the diagnosis, evaluation, and 
treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011; 
128(5):1007–1022. [PubMed: 22003063] 
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5. 
Washington, DC: American Psychiatric Association; 2013. 
Anderson, NJ., Neuwirth, SJ., Lenardson, JD., Hartley, D. Patterns of care for rural and urban children 
with mental health problems. 2013. Retrieved from https://www.ruralhealthresearch.org/
publications/883
Bloom, B., Black, LI., Freeman, G. Tables of summary health statistics for U.S. children: 2013 
National Health Interview Survey. 2015. Retrieved from http://www.cdc.gov/nchs/nhis/SHS/
tables.htm
Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health 
Interview Survey, 2011. Vital and Health Statistics. 2012; 10(254):1–88.
Bloom, B., Freeman, G. Tables of summary health statistics for U.S. children: 2014 National Health 
Interview Survey. 2015. Retrieved from http://www.cdc.gov/nchs/nhis/SHS/tables.htm
Bloom B, Jones LI, Freeman G. Summary health statistics for U.S. children: National health interview 
survey, 2012. Vital and Health Statistics. 2013; 10(258):1–81.
Danielson et al. Page 12
J Clin Child Adolesc Psychol. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bloom, B., Simpson, JL. Tables of summary health statistics for U.S. children: 2015 national health 
interview survey. 2016. Retrieved from http://www.cdc.gov/nchs/nhis/SHS/tables.htm
Charach A, Carson P, Fox S, Ali MU, Beckett J, Lim CG. Interventions for preschool children at high 
risk for ADHD: A comparative effectiveness review. Pediatrics. 2013; 131(5):e1584–e1604. 
[PubMed: 23545375] 
Coker TR, Elliott MN, Toomey SL, Schwebel DC, Cuccaro P, Tortolero Emery S, … Schuster MA. 
Racial and ethnic disparities in ADHD diagnosis and treatment. Pediatrics. 2016; 138(3)doi: 
10.1542/peds.2016-0407
Danielson ML, Visser SN, Chronis-Tuscano A, DuPaul GJ. A national description of treatment among 
U.S. children and adolescents with ADHD. Journal of Pediatrics. 2017a; doi: 10.1016/j.jpeds.
2017.08.040
Danielson ML, Visser SN, Gleason MM, Peacock G, Claussen AH, Blumberg SJ. A national profile of 
attention-deficit hyperactivity disorder diagnosis and treatment among US children aged 2 to 5 
years. Journal of Developmental and Behavioral Pediatrics. 2017b; 38(7):455–464. [PubMed: 
28723824] 
Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, … Murray CJ. US spending on 
personal health care and public health, 1996–2013. JAMA : the Journal of the American Medical 
Association. 2016; 316(24):2627–2646. [PubMed: 28027366] 
Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, … Neumann PJ. Economic 
impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. Journal 
of the American Academy of Child and Adolescent Psychiatry. 2012; 51(10):990–1002. e1002. 
[PubMed: 23021476] 
Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and 
adolescents with attention-deficit/hyperactivity disorder. Journal of Clinical Child & Adolescent 
Psychology. 2014; 43(4):527–551. [PubMed: 24245813] 
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity 
disorder: A meta-analysis of follow-up studies. Psychological Medicine. 2006; 36(2):159–165. 
[PubMed: 16420712] 
Fiks AG, Ross ME, Mayne SL, Song L, Liu W, Steffes J, Wasserman R. Preschool ADHD diagnosis 
and stimulant use before and after the 2011 aap practice guideline. Pediatrics. 2016; 138(6):1–9. 
DOI: 10.1542/peds.2016-2025
Fleming M, Fitton CA, Steiner MFC, McLay JS, Clark D, King A, … Pell JP. Educational and health 
outcomes of children treated for attention-deficit/hyperactivity disorder. JAMA Pediatrics. 2017; 
171(7)doi: 10.1001/jamapediatrics.2017.0691
Fletcher JM. The effects of childhood ADHD on adult labor market outcomes. Health Economics. 
2014; 23(2):159–181. [PubMed: 23427026] 
Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, … Zeanah CH. 
Psychopharmacological treatment for very young children: Contexts and guidelines. Journal of the 
American Academy of Child and Adolescent Psychiatry. 2007; 46(12):1532–1572. [PubMed: 
18030077] 
Groenman AP, Janssen TWP, Oosterlaan J. Childhood psychiatric disorders as risk factor for 
subsequent substance abuse: A meta-analysis. Journal of the American Academy of Child and 
Adolescent Psychiatry. 2017; 56(7):556–569. [PubMed: 28647007] 
Holbrook JR, Cuffe SP, Cai B, Visser SN, Forthofer MS, Bottai M, … McKeown RE. Persistence of 
parent-reported ADHD symptoms from childhood through adolescence in a community sample. 
Journal of Attention Disorders. 2016; 20(1):11–20. [PubMed: 24994874] 
Kelleher KJ, Gardner W. Out of sight, out of mind–Behavioral and developmental care for rural 
children. New England Journal of Medicine. 2017; 376(14):1301–1303. [PubMed: 28301297] 
Little, RJA., Rubin, DB. Statistical analysis with missing data. 2. Hoboken, NJ: Wiley; 2002. 
Matte B, Anselmi L, Salum GA, Kieling C, Goncalves H, Menezes A, … Rohde LA. ADHD in 
DSM-5: A field trial in a large, representative sample of 18- to 19-year-old adults. Psychological 
Medicine. 2015; 45(2):361–373. [PubMed: 25066615] 
McKeown RE, Holbrook JR, Danielson ML, Cuffe SP, Wolraich ML, Visser SN. The impact of case 
definition on attention-deficit/hyperactivity disorder prevalence estimates in community-based 
Danielson et al. Page 13
J Clin Child Adolesc Psychol. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
samples of school-aged children. Journal of the American Academy of Child and Adolescent 
Psychiatry. 2015; 54(1):53–61. [PubMed: 25524790] 
Molina BSG, Hinshaw SP, Arnold LE, Swanson JM, Pelham WE, Hechtman L, … Marcus S. 
Adolescent substance use in the Multimodal Treatment study of Attention-Deficit/Hyperactivity 
Disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood 
treatments, and subsequent medication. Journal of the American Academy of Child and 
Adolescent Psychiatry. 2013; 52(3):250–263. [PubMed: 23452682] 
Morgan PL, Staff J, Hillemeier MM, Farkas G, Maczuga S. Racial and ethnic disparities in ADHD 
diagnosis from kindergarten to eighth grade. Pediatrics. 2013; 132(1):85–93. [PubMed: 23796743] 
Nyarko KA, Grosse SD, Danielson ML, Holbrook JR, Visser SN, Shapira SK. Treated prevalence of 
attention-deficit/hyperactivity disorder increased from 2009 to 2015 among school-aged children 
and adolescents in the United States. Journal of Child and Adolescent Pyschopharmacology. 2017; 
27(8):731–734.
Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit 
hyperactivity disorder. American Journal of Psychiatry. 2003; 160(6):1071–1077. [PubMed: 
12777264] 
Perou R, Bitsko RH, Blumberg SJ, Pastor P, Ghandour RM, Gfroerer JC, … Huang LN. Mental health 
surveillance among children–United States, 2005–2011. Morbidity and Mortality Weekly Report. 
2013; 62(Suppl 2):1–35. [PubMed: 23302815] 
Ros R, Graziano PA. Social functioning in children with or at risk for attention deficit/hyperactivity 
disorder: A meta-analytic review. Journal of Clinical Child and Adolescent Psychology. 2017; :1–
23. DOI: 10.1080/15374416.2016.1266644
Sibley MH, Waxmonsky JG, Robb JA, Pelham WE. Implications of changes for the field: ADHD. 
Journal of Learning Disabilities. 2013; 46(1):34–42. [PubMed: 23128456] 
United States Census Bureau, Associate Director of Demographic Programs, National Survey of 
Children’s Health. 2016 National Survey of Children’s Health frequently asked questions. 2017. 
Retrieved from https://mchb.hrsa.gov/data/national-surveys/data-user
United States Department of Health and Human Services. Healthy people 2020: Improving the health 
of Americans. 2010. Retrieved from https://www.healthypeople.gov/2020/topics-objectives/topic/
early-and-middle-childhood/objectives
Visser SN, Bitsko RH, Danielson ML, Ghandour RM, Blumberg SJ, Schieve LA, … Cuffe SP. 
Treatment of attention deficit/hyperactivity disorder among children with special health care 
needs. Journal of Pediatrics. 2015a; 166(6):1423–1430. e1422. [PubMed: 25841538] 
Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, … Blumberg SJ. 
Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/
hyperactivity disorder: United States, 2003–2011. Journal of the American Academy of Child and 
Adolescent Psychiatry. 2014; 53(1):34–46. e32. [PubMed: 24342384] 
Visser SN, Danielson ML, Bitsko RH, Perou R, Blumberg SJ. Convergent validity of parent-reported 
attention-deficit/hyperactivity disorder diagnosis: A cross-study comparison. JAMA Pediatrics. 
2013; 167(7):674–675. [PubMed: 23700143] 
Visser SN, Danielson ML, Wolraich ML, Fox MH, Grosse SD, Valle LA, … Peacock G. Vital signs: 
National and state-specific patterns of attention deficit/hyperactivity disorder treatment among 
insured children aged 2–5 Years - United States, 2008–2014. Morbidity and Mortality Weekly 
Report. 2016; 65(17):443–450. [PubMed: 27149047] 
Visser SN, Zablotsky B, Holbrook JR, Danielson ML, Bitsko RH. Diagnostic experiences of children 
with attention-deficit/hyperactivity disorder. National Health Statistics Reports. 2015b; 81:1–7.
Wolraich M, Brown L, Brown R. Implementing the key action statements: An algorithm and 
explanation for process of care for the evaluation, diagnosis, treatment, and monitoring of ADHD 
in children and adolescents. Pediatrics. 2011; 128(5):1007–1022. [PubMed: 22003063] 
Danielson et al. Page 14
J Clin Child Adolesc Psychol. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 1. 
Weighted prevalence estimates of parent-reported attention deficit/hyperactivity disorder 
(ADHD) diagnosis among children and adolescents by age, National Survey of Children’s 
Health, 2016.
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FIGURE 2. 
Weighted prevalence estimates of nonmutually exclusive parent-reported treatment types 
among children and adolescents with current attention deficit/hyperactivity disorder by age, 
National Survey of Children’s Health, 2016. Note: Shaded area represents 95% confidence 
interval for treatment point estimates by age. Children receiving both medication and 
behavioral treatment are represented in both lines.
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FIGURE 3. 
Weighted prevalence estimates and 95% confidence intervals for children who have ever 
received an ADHD diagnosis from a health care provider, National Survey of Children’s 
Health (NSCH; 2011–2012–2016) and National Health Interview Survey (NHIS; 2011–
2015).
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